Edgewise Therapeutics Inc.
EWTX | NASDAQ
$44.64
-$0.68 (-1.50%)
At close: Sep 21, 2026, 4:00 PM ET
$44.79
+$0.15 (+0.34%)
Pre-market:
Sep 22, 2026, 5:31 AM ET
Company Profile
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Key Executives
| Name | Position |
|---|---|
| Kevin Koch | President, Chief Executive Officer & Director |
| Behrad Derakhshan | Chief Operating Officer |
| Michael Nofi | Chief Financial Officer |
| Alan J. Russell | Co-Founder, Chief Scientific Officer & Director |
| Aylin Tugcu | Senior Vice President of Cardiovascular Clinical Development & Medical Affairs |
| Badreddin Edris | Co-Founder & Independent Director |
| Joanne Donovan | Chief Medical Officer |
| John R. Moore | General Counsel |
| Peter A. Thompson FACP | Co-Founder & Independent Chairman |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 17, 2026 | 4/A | [Amend] Filing |
| Aug 17, 2026 | 4/A | [Amend] Filing |
| Aug 17, 2026 | 4/A | [Amend] Filing |
| Aug 17, 2026 | 4/A | [Amend] Filing |
| Aug 17, 2026 | 4/A | [Amend] Filing |
| Aug 14, 2026 | 4 | Filing |
| Aug 14, 2026 | 4 | Filing |
| Aug 14, 2026 | 4 | Filing |
| Aug 14, 2026 | 4 | Filing |
| Aug 14, 2026 | 4 | Filing |
Edgewise Therapeutics Inc.
| Country | United States |
| IPO Date | Mar 25, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 127 |
| CEO | Kevin Koch |
Contact Details
1715 38th Street Boulder,
Colorado 80301 United States
Stock Details
| Ticker Symbol | EWTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001710072 |
| CUSIP Number | 28036F105 |
| ISIN Number | US28036F1057 |
| SIC Code | 2834 |
Recent News
- 29 days ago / prnewswire.comEdgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026
- 1 month ago / seekingalpha.comEdgewise Therapeutics: The Servier Deal Creates A Self-Funded Cardiovascular Platform
- 2 months ago / prnewswire.comEdgewise Therapeutics Reports Second Quarter 2026 Financial Results
- 2 months ago / prnewswire.comEdgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline
- 3 months ago / seekingalpha.comEdgewise Therapeutics, Inc. (EWTX) Discusses Top Line Data From EDG-7500 Phase II CIRRUS-HCM Trial in Hypertrophic Cardiomyopathy Transcript
- 3 months ago / benzinga.comEdgewise Therapeutics Reports Improvements In Heart Drug Trial
- 3 months ago / reuters.comEdgewise shares slip after heart-disease drug trial data disappoints investors
- 4 months ago / seekingalpha.comEdgewise: 'Buy' On Muscular Dystrophy Program Sale And EDG-7500 Advancement
- 4 months ago / zacks.comEdgewise Therapeutics Stock Hits Record High on $2.65B Servier Deal
- 4 months ago / reuters.comEdgewise to sell muscle dystrophy business to Servier for up to $2.65 billion
Add to Watchlist
Select watchlists to add or remove EWTX